Neuronetics Names Dan Reuvers CEO as Sullivan Retires
Event summary
- Dan Reuvers appointed President and CEO of Neuronetics, effective March 23, 2026, succeeding Keith Sullivan.
- Reuvers brings 30 years of medical technology leadership, including growing Tactile Medical's revenue from $187M to $300M.
- Sullivan retires after 5.5 years, having transformed Neuronetics into a vertically integrated mental health platform.
- Reuvers received an inducement grant of 1,500,000 restricted stock units vesting over three years.
The big picture
Neuronetics' leadership change comes as the company seeks to expand its market reach in the neurohealth sector. Reuvers' background in scaling medical technology businesses and managing direct billing models aligns with Neuronetics' goal of improving access to treatments for underserved patient populations. The transition follows Sullivan's successful transformation of Neuronetics into a vertically integrated mental health platform, positioning the company for its next phase of growth.
What we're watching
- Revenue Growth
- How Reuvers' track record of scaling medical technology businesses will translate to Neuronetics' growth strategy.
- Market Expansion
- Whether Neuronetics can sustain its national clinic network growth under new leadership.
- Integration Success
- The pace at which Reuvers can integrate his experience in direct billing models into Neuronetics' operations.